| Texto completo | |
| Autor(es): Mostrar menos - |
Lengert, Andre van Helvoort
;
Braga Pereira, Leticia do Nascimento
;
Martins Cabral, Eduardo Ramos
;
Faria Gomes, Izabela Natalia
;
de Jesus, Lais Machado
;
Santiago Goncalves, Maria Fernanda
;
da Rocha, Aline Oliveira
;
Tassinari, Tiago Alexandre
;
da Silva, Luciane Sussuchi
;
Laus, Ana Carolina
;
Vidal, Daniel Onofre
;
Pinto, Mariana Tomazini
;
Reis, Rui Manuel
;
Lopes, Luiz Fernando
Número total de Autores: 14
|
| Tipo de documento: | Artigo Científico |
| Fonte: | FRONTIERS IN BIOSCIENCE-LANDMARK; v. 27, n. 8, p. 13-pg., 2022-08-15. |
| Resumo | |
Background: Testicular germ cell tumors (TGCTs), a group of heterogeneous neoplasms, are the most frequent tumors of teenagers and young men, with the incidence rising worldwide. High cure rates can be achieved through cisplatin (CDDP)-based treatment, but approximately 10% of patients present refractory disease and virtually no treatment alternatives. Here, we explored new strategies to treat CDDP-resistant. Methods: In vitro TGCT CDDP-resistance model was established and differential mRNA expression profiles were evaluated using NanoString technology. Then, TGCT cell lines were treated with four potential drugs (PCNA-I1, ML323, T2AA, and MG-132) to overcome CDDP-resistance. Results: We found several differentially expressed genes related to DNA repair and cell cycle regulation on CDDP-resistant cell line (NTERA-2R) compared to parental cell line (NTERA-2P), and the proteasome inhibitor MG-132 demonstrated cytotoxic activity in all cell lines evaluated, even at a nanomolar range. MG-132 also enhanced cell lines' sensitivity to CDDP, increasing apoptosis in both NTERA-2P and NTERA-2R. Conclusions: MG-132 emerges as a potential new drug to treat CDDP-resistant TGCT. Targeted therapy based on molecular mechanism insights may contribute to overcome acquired chemotherapy CDDP-resistance. (AU) | |
| Processo FAPESP: | 17/22305-9 - Estudo de biomarcadores de resposta ao cetuximabe e perspectivas do uso de combi-moléculas anti-EGFR em tumores sólidos |
| Beneficiário: | Izabela Natalia Faria Gomes |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |